CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

CHAPTER 4 IMATINIB DRUG MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CHRONIC EOSINOPHILIC LEUKEMIA (CEL)

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. DERMATOFIBROSARCOMA PROTUBERANS (DFSP)

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. GASTROINTESTINAL STROMAL TUMORS (GIST)

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. HYPER-EOSINOPHILIC SYNDROME (HES)

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. MYELODYSPLASTIC SYNDROME (MDS)

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

4.8. MYELOPROLIFERATIVE DISEASES (MPD)

4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast

4.9. PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)

4.9.1. Key market trends
4.9.2. Growth factors and opportunities
4.9.3. Market size and forecast

4.10. PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML)

4.10.1. Key market trends
4.10.2. Growth factors and opportunities
4.10.3. Market size and forecast

CHAPTER 5 IMATINIB DRUG MARKET, BY DRUG FORMULATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. TABLET

5.2.1. Market size and forecast

5.3. CAPSULE

5.3.1. Market size and forecast

CHAPTER 6 IMATINIB DRUG MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Imatinib Drug Market by Application
6.2.5. North America Imatinib Drug Market by Drug Formulation

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Imatinib Drug Market by Application
6.3.5. Europe Imatinib Drug Market by Drug Formulation

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Imatinib Drug Market by Application
6.4.5. Asia-Pacific Imatinib Drug Market by Drug Formulation

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Latin America market size and forecast
6.5.3.2. Middle East market size and forecast
6.5.3.3. Africa market size and forecast

6.5.4. LAMEA Imatinib Drug Market by Application
6.5.5. LAMEA Imatinib Drug Market by Drug Formulation

CHAPTER 7 COMPANY PROFILES

7.1. NOVARTIS

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. GLENMARK PHARMACEUTICALS LTD.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. SUN PHARMACEUTICALS

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. ACTAVIS GENERICS

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. DR. REDDY'S LABORATORIES

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. SANOFI S.A.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. CIPLA INC.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. APOTEX INC

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. MYLAN PHARMS INC

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments